Innovation Pharmaceuticals Inc (IPIX)

[Cognition]

"Cellceutix’s defensin mimetic compound CTIX1278, was efficacious as compared to a carbapenem antibiotic that is widely used as a last line of defense against drug-resistant, Gram-negative bacteria, including Klebsiella pneumoniae. A second study is now being conducted at multiple dosing levels with various infusion parameters with the goal of increasing efficacy and further defining a treatment protocol for the compound".

Wonder how that second study is going. Wonder what they'll call CTIX1278. CTIX has a potential platform in its Pipeline. A Defensin Mimetic Platform! How many companies can say that?